A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : HTPR / high on-treatment platelet reactivity

[Related PubMed/MEDLINE]
Total Number of Papers: 162
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   HTPR  (>> Co-occurring Abbreviation)
Long Form:   high on-treatment platelet reactivity
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 ---
2022 A study of microRNA-223 in evaluating platelet reactivity in patients with acute ischemic stroke. ADP-PAg, AIS, LOF, PCR, PRI, VASP
2022 Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial. MEA, STEMI, VASP-P
2022 Circulating Microvesicles in Convalescent Ischemic Stroke Patients: A Contributor to High-On-Treatment Residual Platelet Reactivity? AUC, PMVs
2022 Dual Antiplatelet Therapy with 3rd Generation P2Y12 Inhibitors in STEMI Patients: Impact of Body Mass Index on Loading Dose-Response. BMI, LD
2022 Effects of ticagrelor monotherapy vs. clopidogrel monotherapy on platelet reactivity: a randomized, crossover clinical study (SINGLE study). LTA, PAgR, TEG
2022 High on-treatment platelet reactivity is associated with poor outcomes after ischemic stroke: A meta-analysis. NIHSS, RR, TIA
2022 High on-treatment platelet reactivity to aspirin in patients after myocardial infarction. ---
2022 High On-Treatment Platelet Reactivity: Aspirin versus Clopidogrel. MoA, OAC, PCI, SAPT
10  2022 High triglyceride is an independent predictor of high on-treatment platelet reactivity in ischemic stroke patients. ADPi, CI, DAPT, IS, NTPR, OR, TEG, TG
11  2022 Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis. ACS, LD, LTPR, MEA, MTD, PR, VASP
12  2022 Long-term effects of baseline on-treatment platelet reactivity in patients with acute coronary syndrome and thrombocytopenia undergoing percutaneous coronary intervention. ACS, CAD, LTPR, NTPR, PCI, TP, TPR
13  2021 A Systematic Review and Meta-Analysis on the Impact of High On-Treatment Platelet Reactivity on Clinical Outcomes for Patients Taking ADP Receptor Inhibitors Following Lower Limb Arterial Endovascular Intervention. ADP, GRADE
14  2021 Aspirin I.V. Loading during Elective Percutaneous Coronary Intervention. ASA, CI, MACCE, MACCEs, MoA, OR, PCIs
15  2021 Association between renal function and platelet reactivity during aspirin therapy in elderly patients with atherosclerotic cardiovascular disease. eGFR
16  2021 High On-Treatment Platelet Reactivity as Predictor of Long-term Clinical Outcomes in Stroke Patients with Antiplatelet Agents. ---
17  2021 Impact of high on-treatment platelet reactivity after angioplasty in patients with critical limb ischemia. CLI, DAPT, LTA, MACCE, MALE, PAD, PTA, VASP
18  2021 Novel Predictors of Future Vascular Events in Post-stroke Patients-A Pilot Study. LB, mPFT, NAR, WB
19  2021 Similar Inflammatory Biomarkers Reflect Different Platelet Reactivity in Percutaneous Coronary Intervention Patients Treated With Clopidogrel: A Large-Sample Study From China. ADP, CHD, hs-CRP, LTPR, PCI, TEG
20  2021 [Effect of platelet reactivity on clinical events in patients using bivalirudin in selective percutaneous coronary intervention]. BARC, LTPR, MAADP, MACCE, NTPR, PCI, TEG
21  2020 Aspirin Resistance Affects Medium-Term Recurrent Vascular Events after Cerebrovascular Incidents: A Three-Year Follow-up Study. CI, HR, NTPR, OR
22  2020 Association of clopidogrel high on-treatment reactivity with clinical outcomes and gene polymorphism in acute ischemic stroke patients: An observational study. ADP, LOF, LTA
23  2020 Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease. CAD, EMs, FMO3, IMs, LD, MD, PCR-RFLP, PMs, PRI
24  2020 Clopidogrel responder status is uninfluenced by CYP2C19*2 in Danish patients with stroke. ADP, IS, PRU, SNPs, TIAs
25  2020 Genotype-guided antiplatelet therapy compared with standard therapy for patients with acute coronary syndromes or undergoing percutaneous coronary intervention: A systematic review and meta-analysis. ACS, CI, MACEs, MI, PCI, RCTs, RR, ST, TVR
26  2020 Impact of Continuous P2Y12 Inhibition Tailoring in Acute Coronary Syndrome and Genetically Impaired Clopidogrel Absorption. ---
27  2020 Impact of high on-treatment platelet reactivity after angioplasty in patients with peripheral arterial disease. CI, DAPT, HR, LTA, MACCE, MALE, PAD, VASP
28  2020 Intake of aspirin prior to metamizole does not completely prevent high on treatment platelet reactivity. AA, COX-1, IA, LTA
29  2020 Net platelet clot strength of thromboelastography platelet mapping assay for the identification of high on-treatment platelet reactivity in post-PCI patients. MA, MAadp, PCI, TEGaradp, TEGpm
30  2020 Outcomes and strategy of tailored antiplatelet therapy with ticagrelor in patients undergoing transcarotid artery revascularization. DAPT, TCAR
31  2020 Should CYP2C19 Genotyping Be Recommended as a Straight Forward Approach to Optimize Clopidogrel Utilization in Patients with Ischemic Stroke Complicated by Type 2 Diabetes Mellitus? CI, IS, OR, PCR-RFLP, PIADP, T2DM, TEG
32  2019 Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation. DAPT
33  2019 Between a rock and a hard place: a high-risk patient with resistance to multiple P2Y12 antagonists. LOF, LVAD
34  2019 Clinical outcomes and predictive model of platelet reactivity to clopidogrel after acute ischemic vascular events. MACEs
35  2019 Enhanced Platelet Reactivity under Aspirin Medication and Major Adverse Cardiac and Cerebrovascular Events in Patients with Coronary Artery Disease. CAD, MACCE, MoA, NSTEMI
36  2019 Genotype-guided personalization of antiplatelet treatment: A meta-analysis of patients with ACS or undergoing PCI. ACS, HR, MI, PCI, ST, STD, TVR
37  2019 Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study). ACS, ADP, IR, LTA, TEG
38  2019 Platelet reactivity patterns in patients treated with dual antiplatelet therapy. AA, ACS, ADP, DAPT
39  2019 Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing. LTPR
40  2019 [Relation of Functional Activity of Platelets to Prognosis of Unfavorable Cardiovascular Events in Patients with Acute Coronary Syndrome. Results of a Registry Study]. ACS
41  2018 CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han. CAD, DAPT, LD, MD, NTPR, PCI, PCR-RFLP, PRI, SNPs
42  2018 Dose reduction, oral application, and order of intake to preserve aspirin antiplatelet effects in dipyrone co-medicated chronic artery disease patients. AA, CAD, LTA
43  2018 Effect of cilostazol on platelet reactivity among patients with peripheral artery disease on clopidogrel therapy. PAD
44  2018 Effectiveness of Platelet Function Analyzer-100 for Laboratory Detection of Anti-Platelet Drug-Induced Platelet Dysfunction. CT, NSAIDs, PFA
45  2018 H2 Receptor Antagonists versus Proton Pump Inhibitors in Patients on Dual Antiplatelet Therapy for Coronary Artery Disease: A Systematic Review. DAPT, GI, H2RAs, MACE, PPIs
46  2018 High On-Treatment Platelet Reactivity in Danish Hyper-Acute Ischaemic Stroke Patients. IS, TIAs
47  2018 Impact of immature platelet fraction on platelet reactivity during prasugrel maintenance treatment. DAPT, IPF, PCIs
48  2018 Malondialdehyde Assay in the Evaluation of Aspirin Antiplatelet Effects. LTA, MDA, TX
49  2018 Pharmacogenetic association study on clopidogrel response in Puerto Rican Hispanics with cardiovascular disease: a novel characterization of a Caribbean population. OR
50  2018 Pharmacometabolomics analysis of plasma to phenotype clopidogrel high on treatment platelets reactivity in coronary artery disease patients. CAD, DAPT, IAP, LD, PCI
51  2018 Platelet function testing: dead or alive. LTA, LTPR, MP, VASP
52  2018 Risk of discontinuation of clopidogrel after 1 month following bare-metal stents: a propensity-score adjusted comparison with continued administration of clopidogrel after drug-eluting stents. BMS, MI, PCI
53  2018 Role of Dipyrone in the High On-Treatment Platelet Reactivity amongst Acetylsalicylic Acid-Treated Patients Undergoing Peripheral Artery Revascularisation. ASA
54  2018 Secondary Stroke Prophylaxis with Clopidogrel Produces Sufficient Antiplatelet Response. AMI, IS, TIA
55  2017 1H NMR based pharmacometabolomics analysis of urine identifies metabolic phenotype of clopidogrel high on treatment platelets reactivity in coronary artery disease patients. CAD, LD
56  2017 Acetylsalicylic acid in critically ill patients: a cross-sectional and a randomized trial. ASA, TXB2
57  2017 Add-on Antiplatelet Effects of Eicosapentaenoic Acid With Tailored Dose Setting in Patients on Dual Antiplatelet Therapy. AA, EPA, MPA
58  2017 Administration of Ticagrelor and Double-Dose Clopidogrel Based on Platelet Reactivity Determined by VerifyNow-P2Y12 for Chinese Subjects After Elective PCI. PCI, PRU
59  2017 Clinical determinants of clopidogrel responsiveness in a heterogeneous cohort of Puerto Rican Hispanics. ADP, CCBs, CI, DM, OR, PPIs
60  2017 Evaluation of On-Clopidogrel platelet reactivity overtime, SYNTAX SCORE, genetic polymorphisms and their relationship to one year clinical outcomes in STEMI patients undergoing PCI. MACE, PAI, PCI, SS, STEMI
61  2017 Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome. ACS, LOF
62  2017 Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity. ACS, ADP, TEG
63  2017 High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: A systematic review and meta-analysis. DAPT, IS, TIA
64  2017 High On-Treatment Platelet Reactivity to Adenosine Diphosphate Predicts Ischemic Events of Minor Stroke and Transient Ischemic Attack. TEG-ADPMA, TIA
65  2017 On-clopidogrel platelet reactivity as predictor for long-term clinical outcome in patients after planned discontinuation of clopidogrel. ---
66  2017 Optimal Same-Day Platelet Inhibition in Patients Receiving Drug-Eluting Stents With or Without Previous Maintenance Thienopyridine Therapy: from the Evaluation of Platelet Inhibition in Patients Having A VerifyNow Assay (EPIPHANY) Trial. EPIPHANY, PCI
67  2017 Proteinuria Predicts Resistance to Antiplatelet Therapy in Ischemic Stroke. ---
68  2017 Relationship between clopidogrel-related polymorphisms and variable platelet reactivity at 1 year: A cohort study from Han Chinese. ---
69  2017 Thromboxane Formation Assay to Identify High On-Treatment Platelet Reactivity to Aspirin. AA, LTA, TX
70  2017 Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention. LTPR, PCI
71  2017 [Predictive value of serial platelet function testing on outcome in patients undergoing complex percutaneous coronary intervention]. DAPT, MACCE, PCI, PFT
72  2016 Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients. ADP, GP, STEMI
73  2016 Association between high on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention. DES, MEA, PCI
74  2016 Cardiovascular events occur independently of high on-aspirin platelet reactivity and residual COX-1 activity in stable cardiovascular patients. COX, CVEs, TX
75  2016 Clinical significance of platelet reactivity during prasugrel therapy in patients with acute myocardial infarction. AMI, CI, OR, PCI, PR
76  2016 Clopidogrel High On-Treatment Platelet Reactivity in Patients with Carotid Artery Stenosis Undergoing Endarterectomy. A Pilot Study. CEA, MEA
77  2016 Current status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implications. ---
78  2016 Does Pantoprazole Affect the On-Treatment Platelet Reactivity in Patients With Acute STEMI Treated With ADP Receptor Blockers?-A Pilot Prospective Study. ADP, PPI, STEMI
79  2016 Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy. ACS, TPR, VASP
80  2016 Effect of Modifying Antiplatelet Treatment to Ticagrelor in High-Risk Coronary Patients With Low Response to Clopidogrel (MATTIS). PCI
81  2016 Efficacy of prasugrel administration immediately after percutaneous coronary intervention in ST-elevation myocardial infarction. MCP, PCI, PRI, STEMI
82  2016 Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity. CAD, LTPR
83  2016 Genotype Frequencies of CYP2C19, P2Y12 and GPIIIa Polymorphisms in Coronary Heart Disease Patients of Han Ethnicity, and Their Impact on Clopidogrel Responsiveness. MACEs
84  2016 High on-treatment platelet reactivity: risk factors and 5-year outcomes in patients with acute myocardial infarction. DPR, HR, MI, PRA, PRC
85  2016 Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention. ACS, LD, MD, PCI, VASP
86  2016 Relationship between ADP-induced platelet-fibrin clot strength and anti-platelet responsiveness in ticagrelor treated ACS patients. ACS, LTPR, TEG, TIMI
87  2016 The first six-month clinical outcomes and risk factors associated with high on-treatment platelet reactivity of clopidogrel in patients undergoing coronary interventions. PCI
88  2016 Ticagrelor versus prasugrel in patients with high on-clopidogrel treatment platelet reactivity after PCI: The ISAR-ADAPT-PF study. AU, CI, LD, MD, PCI
89  2016 Type 2 Diabetes and ADP Receptor Blocker Therapy. T2D
90  2015 Antiplatelet drugs in patients with enhanced platelet turnover: biomarkers versus platelet function testing. ---
91  2015 Antiplatelet effects of aspirin in chronic kidney disease patients. CI, CKD, IQR
92  2015 Antiplatelet effects of clopidogrel and aspirin after interventional patent foramen ovale/ atrium septum defect closure. ASD, LTA, PFO, VASP
93  2015 Changes in platelet function independent of pharmacotherapy following coronary intervention in non-ST-elevation myocardial infarction patients. ACS, AU, MEA, PCI
94  2015 CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis. CI, IM, LOF, PG-PRT, QALYs
95  2015 CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome. ACS, ADP, EMs, GOF, IMs, LOF, PIR, PMs, TEG
96  2015 High maintenance dose of clopidogrel in patients with high on-treatment platelet reactivity after a percutaneous coronary intervention: a meta-analysis. CI, CV, MD, RR
97  2015 High On-Treatment Platelet Reactivity Associated With Prasugrel. MI
98  2015 High on-treatment platelet reactivity in transcatheter aortic valve implantation patients. DAPT, LTPR, TAVI
99  2015 High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis. ---
100  2015 Inter-patient variability of platelet reactivity in patients treated with prasugrel and ticagrelor. ADP, LTPR